Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma

Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma

Sitki Samet ErmişFaculty of Medicine, Balikesir University, Tip Fak&uuml;ltesi, &Ccedil;agis Kamp&uuml;s&uuml;, Balikesir, TurkeyAbstract: Glaucoma is a chronic disease requiring lifelong treatment. Discomfort due to medications may affect patients&#39; qualit...

Full description

Bibliographic Details
Main Author:	Ermiş&nbsp;SS
Format:	Article
Language:	English
Published:	Dove Medical Press 2012-05-01
Series:	Clinical Ophthalmology
Online Access:	http://www.dovepress.com/differential-pharmacology-and-clinical-utility-of-preservative-free-ta-a9840

Similar Items

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension
by: Lanzl I, et al.
Published: (2013-05-01)

Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
by: Ruangvaravate N, et al.
Published: (2020-10-01)

Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension
by: Clyde Schultz
Published: (2011-06-01)

Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension
by: Clyde Schultz
Published: (2011-01-01)

Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
by: Pacella F, et al.
Published: (2012-06-01)

Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost
by: Naoto Tokuda, et al.
Published: (2017-01-01)

Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension
by: Makoto Aihara
Published: (2010-03-01)

Efficacy and tolerability of preservative-free tafluprost 0.0015% in Korean patients with glaucoma
by: Hwang YH
Published: (2013-12-01)

Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
by: Dorota Pozarowska
Published: (2010-10-01)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
by: Sacchi M, et al.
Published: (2014-09-01)

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study
by: Pillunat LE, et al.
Published: (2017-06-01)

Comparison of Ocular Pulse Amplitude Lowering Effects of Preservative-Free Tafluprost and Preservative-Free Dorzolamide-Timolol Fixed Combination Eyedrops
by: Du Ri Seo, et al.
Published: (2015-01-01)

Comparison of the Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost
by: Joon Mo Kim, et al.
Published: (2021-05-01)

Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study
by: Wonseok Lee, et al.
Published: (2017-04-01)

Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study
by: Teresa Rolle, et al.
Published: (2017-08-01)

The clinical effectiveness of tafluprost on Japanese normal-tension glaucoma patients
by: Nomura A, et al.
Published: (2018-03-01)

Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost
by: Hommer A, et al.
Published: (2011-05-01)

Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog
by: Yoshimi Niwano, et al.
Published: (2014-01-01)

Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog
by: Yoshimi Niwano, et al.
Published: (2014-02-01)

Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma
by: Janulevičienė I, et al.
Published: (2012-01-01)

Efficacy and safety of 0.0015% tafluprost versus 0.005% latanoprost in primary open angle glaucoma, ocular hypertension: a Meta-analysis
by: Xi-Ting Yang, et al.
Published: (2020-03-01)

Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients
by: Wissam Georges El Hajj Moussa, et al.
Published: (2018-01-01)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
by: Pillunat LE, et al.
Published: (2016-09-01)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
by: Gregory Katz, et al.
Published: (2010-11-01)

Crossover randomized study comparing the efficacy and tolerability of preservative-free Tafluprost 0.0015% to Latanoprost 0.005% in patients with primary open-angle glaucoma
by: Sherein M Hagras, et al.
Published: (2021-01-01)

Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma
by: Inoue K, et al.
Published: (2013-07-01)

Impact of tafluprost and tafluprost/timolol on the thickness of the retina in the macular area
by: N. I. Kurysheva, et al.
Published: (2019-03-01)

Tolerability and effectiveness of preservative-free dorzolamide&ndash;timolol (preservative-free Cosopt&reg;) in patients with open-angle glaucoma or ocular hypertension
by: Cindy Hutnik, et al.
Published: (2010-06-01)

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
by: Uusitalo H, et al.
Published: (2016-03-01)

Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma
by: Liu Y, et al.
Published: (2012-12-01)

Assessment of the optic nerve head, peripapillary, and macular microcirculation in the newly diagnosed patients with primary open-angle glaucoma treated with topical tafluprost and tafluprost/timolol fixed combination
by: Natalia Ivanovna Kurysheva
Published: (2019-01-01)

Preperimetric Glaucoma Prospective Observational Study (PPGPS): Design, baseline characteristics, and therapeutic effect of tafluprost in preperimetric glaucoma eye.
by: Naoko Aizawa, et al.
Published: (2017-01-01)

MLIP genotype as a predictor of pharmacological response in primary open-angle glaucoma and ocular hypertension
by: María I. Canut, et al.
Published: (2021-01-01)

Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/ timolol among patients with open-angle glaucoma or ocular hypertension
by: Sanseau A, et al.
Published: (2013-02-01)

The 24-hour intraocular pressure control by tafluprost/timolol fixed combination after switching from the concomitant use of tafluprost and timolol gel-forming solution, in patients with primary open-angle glaucoma
by: Nakamoto K, et al.
Published: (2018-02-01)

OCT angiography analysis of retinal vessel density in primary open-angle glaucoma with and without Tafluprost therapy
by: Hannah Weindler, et al.
Published: (2020-11-01)

Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
by: Anna Galanopoulos, et al.
Published: (2008-12-01)

A Prospective Study Evaluating IOP Changes after Switching from a Therapy with Prostaglandin Eye Drops Containing Preservatives to Nonpreserved Tafluprost in Glaucoma Patients
by: Stefano Ranno, et al.
Published: (2012-01-01)

The prevalence of ocular surface complaints in Brazilian patients with glaucoma or ocular hypertension
by: Vital Paulino Costa, et al.
Published: (2013-08-01)

Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension
by: Michele Iester
Published: (2008-10-01)

Cannot write session to /tmp/vufind_sessions/sess_2672ia9ogkq167dkau7nb9o0bb